---
layout: post
title: "E6(R3) Guideline for Good Clinical Practice; International Council for Harmonisation; Draft Guidance for Industry; Availability"
date: 2026-02-05 18:55:47 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-12099
original_published: 2023-06-07 00:00:00 +0000
significance: 8.00
---

# E6(R3) Guideline for Good Clinical Practice; International Council for Harmonisation; Draft Guidance for Industry; Availability

**Published:** February 05, 2026 18:55 UTC
**Source:** Federal Register
**Original Published:** June 07, 2023 00:00 UTC
**Document Number:** 2023-12099

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "E6(R3) Guideline for Good Clinical Practice." The draft guidance was prepared under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The draft guidance outlines modernized Good Clinical Practice considerations to guide thoughtful design and responsible conduct of clinical trials in a manner that ensures participant safety and the reliability of trial results. This draft guidance encourages innovation, focuses on quality, and establishes proportionate and risk- based approaches for conducting clinical trials, while minimizing unnecessary complexities. The draft guidance is intended to provide flexible, modern, and clear Good Clinical Practice for conducting clinical trials.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/07/2023-12099/e6r3-guideline-for-good-clinical-practice-international-council-for-harmonisation-draft-guidance-for)
- API: https://www.federalregister.gov/api/v1/documents/2023-12099

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
